| Chapter title |
Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
|
|---|---|
| Chapter number | 6 |
| Book title |
Mouse Models for Drug Discovery
|
| Published in |
Methods in molecular biology, January 2016
|
| DOI | 10.1007/978-1-4939-3661-8_6 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-3659-5, 978-1-4939-3661-8
|
| Authors |
Derry C. Roopenian, Gregory J. Christianson, Gabriele Proetzel, Thomas J. Sproule |
| Editors |
Gabriele Proetzel, Michael V. Wiles |
| Abstract |
Therapeutic monoclonal antibodies are widely recognized to be a most promising means to treat an increasing number of human diseases, including cancers and autoimmunity. To a large extent, the efficacy of monoclonal antibody treatment is because IgG antibodies have greatly extended persistence in vivo. However, conventional rodent models do not mirror human antibody pharmacokinetics. The key molecule responsible for the extended persistence antibodies is the major histocompatibility complex class I family Fc receptor, FcRn. We describe human FcRn transgenic mouse models and how they can be exploited productively for the preclinical pharmacokinetic evaluation of therapeutic antibodies. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 25% |
| Researcher | 6 | 25% |
| Professor | 2 | 8% |
| Other | 2 | 8% |
| Student > Master | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 4 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 9 | 38% |
| Agricultural and Biological Sciences | 4 | 17% |
| Immunology and Microbiology | 2 | 8% |
| Medicine and Dentistry | 2 | 8% |
| Neuroscience | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 6 | 25% |